Sino Biopharmaceutical : VOLUNTARY ANNOUNCEMENT - "TIANQINGGANMEI" IS INCLUDED IN THE "TREATMENT PRACTICES FOR NOVEL CORONAVIRUS PNEUMONIA (SECOND EDITION)"

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

"TIANQINGGANMEI" IS INCLUDED IN THE "TREATMENT PRACTICES FOR

NOVEL CORONAVIRUS PNEUMONIA (SECOND EDITION)"

The board of directors (the "Board") of Sino Biopharmaceutical Limited (the "Company") hereby announces that the offices of National Health Commission and National Administration of Traditional

Chinese Medicine have jointly published the "Treatment Practices for the Mild and Common Cases of Novel Coronavirus Pneumonia (Second Edition)" (《新型冠狀病毒肺炎輕型、普通型病例管理規範（第

二版）》, "Treatment Practices for Novel Coronavirus Pneumonia (Second Edition)"), which provides guidance for the treatment practices on mild and common patients (without severe underlying illnesses), among which, Magnesium Isoglycyrrhizinate intravenous therapy is included as a supportive treatment.

Magnesium Isoglycyrrhizinate injection (brand name: Tianqingganmei (天晴甘美)) is a Category 1 new drug self-developed by Chia-Tai Tianqing Pharmaceutical Group Co., Ltd, a subsidiary of the Company. It has successively obtained eleven domestic authorized patents and the 10th National Patent Gold Award, and has been a highly recognized hepatitis therapeutic drug in the academia. Recently, a lot of attention has been given to the effectiveness of Magnesium Isoglycyrrhizinate in supporting the treatment of novel coronavirus pneumonia. The novel coronavirus pneumonia virus will produce a large amount of inflammatory factors and oxygen free radicals during the reproduction process, which damage the targeted organs. Magnesium Isoglycyrrhizinate can regulate immune function, exert antiviral effects, and have a clear anti-inflammatory mechanism. Previously, according to the relevant curative cases in places such as Shanghai City, Hangzhou City and Zhejiang Province, Magnesium Isoglycyrrhizinate has shown good efficacy in its clinical practices on novel coronavirus pneumonia.

By order of the Board

Sino Biopharmaceutical Limited

Tse, Theresa Y Y

Chairwoman

Hong Kong, 25 February 2020

As at the date of this announcement, the Board comprises eight Executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and four Independent Non-Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong and Mr. Zhang Lu Fu.